Here the authors show that in mice with a targeted disruption of the autophagy pathway in CD11c+ cells, development of NAFLD is accelerated involving IL-23 and blocking of IL-23 reduces disease. This evidence concerns the gene IL23A and metabolic dysfunction-associated steatotic liver disease.